Form 4: Day One Biopharmaceuticals COO Charles N. York II Reports Stock Transactions

Charles N. York II, COO, CFO, and Secretary of Day One Biopharmaceuticals, Inc., reported the acquisition and disposal of common stock and Restricted Stock Units (RSUs) on August 15 and 16, 2024.

Summary

• On August 15, 2024, Charles N. York II acquired common stock through the vesting of Restricted Stock Units (RSUs).
• Specifically, 1,375, 2,250, and 6,625 shares were acquired as RSUs vested.
• On August 16, 2024, York disposed of 2,633 shares of common stock at a price of $13.9991 per share.
• These sales were solely to cover the reporting person's tax liability with respect to the settlement of RSUs.
• Following these transactions, York directly owns 232,485 shares of Day One Biopharmaceuticals, Inc.
• York also holds 6,875, 20,250, and 86,125 Restricted Stock Units.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and related to stock options and tax obligations. There is no indication of significant positive or negative sentiment.

Positives

• The acquisition of shares through RSU vesting indicates confidence in the company's future performance.

Negatives

• The sale of shares, even for tax purposes, could be perceived negatively by some investors, although the explanation clarifies the reason.

Risks

• Executive stock sales, even for tax obligations, can sometimes create short-term price volatility.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but the impact is likely minimal given the stated reason for the sale.

Key Dates